Global Sustained Release Injectables Market Growth (Status and Outlook) 2023-2029

Global Sustained Release Injectables Market Growth (Status and Outlook) 2023-2029

It is a preparation with better therapeutic effect by delaying drug release rate from the formulation and reducing drug absorption rate into the body.

LPI (LP Information)' newest research report, the “Sustained Release Injectables Industry Forecast” looks at past sales and reviews total world Sustained Release Injectables sales in 2022, providing a comprehensive analysis by region and market sector of projected Sustained Release Injectables sales for 2023 through 2029. With Sustained Release Injectables sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sustained Release Injectables industry.

This Insight Report provides a comprehensive analysis of the global Sustained Release Injectables landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sustained Release Injectables portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sustained Release Injectables market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sustained Release Injectables and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sustained Release Injectables.

The global Sustained Release Injectables market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Sustained Release Injectables is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Sustained Release Injectables is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Sustained Release Injectables is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Sustained Release Injectables players cover AntriaBio, Ascendis Pharma, AstraZeneca, Aurobindo, Avadel, Alkermes, Amylin Pharmaceuticals, Biomarin and Camurus, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Sustained Release Injectables market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Microparticles
Implants
Gels

Segmentation by application
Diabetes
Leukemia
Acromegaly
Ophthalmology
CNS
Rheumatology
Oncology
Reproductive Health
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AntriaBio
Ascendis Pharma
AstraZeneca
Aurobindo
Avadel
Alkermes
Amylin Pharmaceuticals
Biomarin
Camurus
Critical Pharmaceuticals
Durect
Eli Lilly
Enzon
Ipsen
InnoCore Pharmaceuticals
Janssen
Merck
NanOlogy
Novartis
Oakwood Laboratories/PharmaSophia
OctoPlus
Pacira
PhaseBio Pharmaceuticals
Recipharm AB
Roche
Sanofi
Taiwan Liposome Company (TLC)
Xbrane Biopharma
Livzon Pharm
Luye Pharma Group

Please note: The report will take approximately 2 business days to prepare and deliver.